Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Relypsa: Analyzing April Results of the Veltassa Launch (RLYP, Buy, $14.00)

Investment†Overview

Investors are closely watching the launch progress of Veltassa following its December 2015 introduction. Medicare and managed care have set…
Read more…

Relypsa: Update Following 1Q, 2016 Conference Call (RLYP, Buy, $14.15)

Investment Thesis for Relypsa

The investment issues for Relypsa are complex. Its key drug Veltassa was launched in December of 2015…
Read more…